Whitepaper: How BLIS K12™ stimulates an immune response in times of high need
Two new studies have revealed that BLIS K12™ stimulates the production of interferon gamma and immunoglobulin A (sIgA) levels in the mouth…
The latest updates on our probiotic developments and news.
Two new studies have revealed that BLIS K12™ stimulates the production of interferon gamma and immunoglobulin A (sIgA) levels in the mouth…
Upper respiratory illnesses, such as the common cold and flu, have a significant impact on our daily lives. To combat these upper respiratory illnesses naturally, a potential solution may be closer than you think: BLIS K12™. T
John Hale the Chief Technology Officer of Blis will be speaking on the Skin Microbiome and BLIS Q24™ our patented and beneficial strain of bacteria for the skin.
This award recognises outstanding innovation demonstrated in any facet of the entrant’s business. Dunedin-based Blis Technologies develops and manufactures innovative probiotic solutions.
Three independent studies reveal continued support that consumption of Streptococcus salivarius (BLIS K12™) is beneficial in reducing the frequency and length of respiratory illness caused by both viruses and bacteria.
Jennifer Walker and Tim Howlett travelled to Bangkok, Thailand to represent BLIS Technologies at Vitafoods Asia.
Professor John Tagg recently spoke with Dave Asprey of Bulletproof Radio about his years of dedicated research and development of BLIS.
In September 2016, Blis Technologies received two Otago Southland awards in the Deloitte Fast 50 at an event in Dunedin. Fast 50
Blis Technologies, a biotechnology firm based in Dunedin, has been awarded the prestigious 2010 Frost & Sullivan Global Entrepreneurial Company of the